GLP-1 Receptor

Also known as: GLP-1R · glucagon-like peptide-1 receptor

The GLP-1 receptor is the G protein-coupled receptor that GLP-1 activates to boost insulin, lower glucagon, slow the stomach and reduce appetite.

GLP-1 (glucagon-like peptide 1) is a 30-amino-acid hormone made by L-cells in the lining of the gut and released when you eat. Acting through its receptor, it stimulates insulin secretion, which makes it an incretin hormone, and it suppresses glucagon, which together limit the rise in blood glucose after a meal. It also slows movement through the gut as part of the so-called ileal brake and appears to be a physiological regulator of appetite and food intake.

Natural GLP-1 lasts only briefly: the enzyme dipeptidyl peptidase IV (DPP-4) inactivates it so fast that much of it is broken down before it even leaves the gut. That is why drugs targeting this receptor are engineered analogs that resist breakdown rather than GLP-1 itself. The receptor is found on pancreatic islet cells and on other cell types and pathways involved in appetite, inflammation and the cardiovascular system, which is why GLP-1 receptor agonists have effects beyond blood sugar.

Why it matters

What you notice on a GLP-1 receptor agonist, such as less hunger and feeling full sooner, maps onto this receptor's actions on appetite and gut motility. The size of the effect in people is well measured. In the STEP 1 trial, 1,961 adults with overweight or obesity and no diabetes took once-weekly semaglutide 2.4 mg or placebo for 68 weeks alongside a lifestyle program. Mean body weight changed by -14.9% with semaglutide and -2.4% with placebo. Nausea and diarrhea were the most common side effects, usually transient and mild to moderate, and 4.5% of people on semaglutide stopped because of gastrointestinal events versus 0.8% on placebo.

The receptor does not care where an agonist came from. What differs between a prescription product and a research-market vial is identity, dose accuracy and purity, and the receptor biology cannot tell you any of those.

How to read a GLP-1 trial result

Check who was studied: people with type 2 diabetes respond differently from people without it, so do not mix the numbers.
Check the estimand: STEP 1's primary analysis counted everyone regardless of whether they stopped treatment.
Subtract the placebo result to get the treatment effect.
Look at both percent change and kilograms, and at how many people stopped because of side effects.

Placebo-adjusted change = change in the drug group - change in the placebo group

Worked example

STEP 1: -14.9% - (-2.4%) = -12.5 percentage points by simple subtraction; the trial's model-based estimate was -12.4 points. In kilograms: -15.3 kg - (-2.6 kg) = -12.7 kg, matching the reported difference.

Common mistakes

Expecting native GLP-1 or short fragments to act like long-acting analogs; DPP-4 breaks native GLP-1 down very quickly.
Quoting the drug-group weight loss without subtracting the placebo group.
Comparing a diabetes-trial number with an obesity-trial number as if they were the same population.
Assuming every tissue effect reported in GLP-1 research is established in people; several non-glycemic actions are still open questions.

Sources

ReviewThe physiology of glucagon-like peptide 1. Physiol Rev, 2007. PMID 17928588.
ReviewMechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab, 2018. PMID 29617641.
Clinical trialOnce-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med, 2021. PMID 33567185.

Page updated October 3, 2026. How we grade evidence: methodology.

Related Terms

GIP Receptor

The GIP receptor is the receptor for GIP, a gut incretin hormone that boosts insulin after meals; tirzepatide activates it along with the GLP-1 receptor.

GLP-1 Agonist

A GLP-1 agonist is a drug that activates the receptor for glucagon-like peptide-1 (GLP-1), a gut hormone, and is used to lower blood glucose and body weight.

Receptor Desensitization

Receptor desensitization is the drop in a cell's response to a drug or hormone after repeated or continuous stimulation of its receptor.

Receptor Agonist

A receptor agonist is a molecule that binds a receptor and switches it on, producing a response the way the body's own signaling molecule does.

Look up any peptide term inside DoseCraft Pro

The glossary is just the start. Inside DoseCraft you get 90+ compound deep-dives, a PK-aware protocol engine, interaction checker, and vendor trust scores — every term surfaced in protocol-design context, not a separate page.

Start Free Trial